Fusion Antibodies PLC Block admission six monthly return (4463G)

TIDMFAB

RNS Number : 4463G

Fusion Antibodies PLC

01 April 2022

1 April 2022

Fusion Antibodies plc

("Fusion" or the "Company")

Block admission six monthly return

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.

 
 Name of company:                     Fusion Antibodies plc 
 Name of scheme:                      Historic options, EMI and Unapproved 
                                       Employee Share Option Scheme, 
                                       as announced on 27 September 
                                       2021 
                                     -------------------------------------- 
 Period of return:                    From 1 October 2021 to 1 April 
                                       2022 
                                     -------------------------------------- 
 Number and class of securities       917,083 ordinary shares of 4 
  not issued under the scheme          pence each in the Company ("Ordinary 
  at the beginning of the period:      Shares") 
                                     -------------------------------------- 
 Number of securities issued          120,000 Ordinary Shares 
  under the scheme during the 
  period: 
                                     -------------------------------------- 
 Number of options under the          Options over 10,000 Ordinary 
  scheme that have lapsed during       Shares 
  the period: 
                                     -------------------------------------- 
 Balance under the scheme of          787,083 Ordinary Shares 
  securities not yet issued at 
  the end of the period: 
                                     -------------------------------------- 
 Number and class of securities       917,083 Ordinary Shares on 27 
  originally admitted and the          September 2021 
  date of admission: 
                                     -------------------------------------- 
 Contact name and telephone number:   James Fair, CFO via Walbrook 
                                       PR 
                                       [phone] 
                                     -------------------------------------- 
 

Enquiries:

 
 Fusion Antibodies plc                                    www.fusionantibodies.com 
 Simon Douglas, Chairman                                           Via Walbrook PR 
  James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                  Tel: [phone] 
 James Reeve/Vivek Bhardwaj (Corporate 
  Finance) 
  Tony Quirke (Sales and Corporate Broking) 
 
 Walbrook PR                     Tel: [phone] or [e-mail] 
 Anna Dunphy                                                  Mob: [phone] 
                                                                               001 
 Paul McManus                                                 Mob: [phone] 
                                                                               893 
 
 

About Fusion Antibodies plc

Fusion is a Belfast-based Collaborative Research Organisation ("CRO") company, listed on AIM, providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

Fusion provides a broad range of services in antibody generation, development, characterisation, optimisation, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx(TM) platform and cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.

At every stage, our client's vision is central to how we work in combining the latest technological advances with cutting edge science. In this work our world-class humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM) to ensure the best molecule goes to the clinic. Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire will address a continuing market need in antibody discovery,

Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $135.4 billion in 2018 and forecast to surpass $300 billion by 2025, a CAGR of 14.26%. As of May 2021, there were 100 approved antibody therapies on the market and more than 570 antibody therapies in clinical development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRBKCBPQBKDDNB

(END) Dow Jones Newswires

April 01, 2022 02:01 ET (06:01 GMT)